It is still all too fresh in the minds of many patients. Fifty years ago, between the 1970s and 1980s, some 10,000 TMJ patients received Vitek jaw implant devices.
The NIH Common Fund's Acute to Chronic Pain Signatures program aims to understand the biological characteristics underlying the transition from acute to chronic pain and what makes some people susceptible and others resilient to the development of chronic pain.
FDA Public Meeting on Patient-Focused Drug Development for Chronic Pain
On July 9, 2018, FDA hosted a public meeting on Patient-Focused Drug Development for Chronic Pain. https://www.federalregister.gov/documents/2018/05/15/2018-10284/patient-focused-
We were recently contacted by Tom P. who informed us that he was including The TMJ Association (TMJA), in his financial planning. Tom wrote the following for us to share with our readers:
Let's say the National Institutes of Health just handed us a multi-million dollar grant to get to the bottom of TMD and find a cure once and for all. I mean, we could start handing out heating pads left and right, but that kind of relief can only get us so far. Whenever I try a different form of therapy or medication, I like to think about the biology, right down to the cellular and molecular level. Why are the cells that make up my jaw region being such jerks?
The TMJ Association is pleased to partner with Inspire to bring you the TMJ Cafe, a free online support network and discussion community for those with Temporomandibular Disorders (TMD). We invite you to meet others like you, share experiences and tips for getting through the day, and give and receive support.
Temporomandibular disorder (TMD) is a set of heterogeneous musculoskeletal conditions involving the temporomandibular joint (TMJ) and/or the masticatory muscles. Up to 33% of the population has had at least one symptom of TMD with 5-10% of them requiring treatment. Common symptoms include limited jaw movement, joint sound, and pain in the orofacial area. Once TMD becomes chronic, it can be debilitating with comorbidities that greatly reduce one's overall quality of life. However, the underlying mechanism of TMD is unclear due to the multicausative nature of the disease.
Sjӧgren's Syndrome seems to play a role in temporomandibular joint disorders.
The Botox-injected masseters had greatly increased expression of genes involved in muscle atrophy at the 1 week time point compared to the control side muscles. At the end of the study, 2 weeks after injection, the Botox-injected masseters were about 20% smaller than the control side masseters, and the Botox-side condyles had lost about 40% of relative bone area compared to the control side condyles.
We are pleased to introduce Sophia Stone, a new contributor to The TMJ Association, whose passion is to separate TMD fact from TMD fiction. Sophia has a background in medicine and research and can draw on her personal experience as a TMD patient.